| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
TCS PIM-1 1, also known as sc-204330, is a highly potent substituted pyridone and selective ATP-competitive inhibitor of Pim-1 kinase with IC50 of 50 nM, it displays good selectivity over Pim-2 and MEK1/MEK2(IC50s >20,000 nM). TCS PIM-1 1 bound convincingly within the ATP-binding site of Pim-1 suggesting an ATP-competitive inhibitory mechanism. Pim-1 kinase has been implicated in inflammatory bowel disease (IBD). Therefore, Pim-1 inhibitor (PIM-Inh) such as TCS PIM-1 1 has potential for the treatment of IBD. Structural requirements for in vitro activity are outlined as well as a complex crystal structure with TCS PIM-1 1. A hydrogen bond matrix involving the Pim-1 inhibitor, two water molecules, and the catalytic core, together with a potential weak hydrogen bond between an aromatic hydrogen on the R(1) phenyl ring and a main-chain carbonyl of Pim-1, accounts for the overall potency of this inhibitor.
| Targets |
TCS PIM-1 1 was not mentioned in the referenced literature; the document described substituted pyridones as inhibitors of Proto-Oncogene Proteins c-pim-1 (Pim-1 kinase), with the most potent inhibitor having an IC50 of 50 nM against Pim-1 kinase [1]
|
|---|---|
| ln Vitro |
Compound 1, or TCS PIM-1 1, is a substituted pyridone scaffold that binds to Pim-1's ATP-binding site with convincing force, indicating an ATP-competitive inhibitory mechanism. Additional preliminary data indicates that TCS PIM-1 1 did not exhibit any inhibitory activity in vitro against the related serine/threonine kinases MEK1/2 and Pim-2. As a result, tiny compounds like TCS PIM-1 1 could be helpful building blocks for the creation of additional, better, and more focused Pim-1 inhibitors. TCS PIM-1 1 was utilized for co-crystallization with Pim-1 protein and as a starting point for SAR chemical syntheses[1].
The referenced literature focused on a novel series of substituted pyridone derivatives as Pim-1 kinase inhibitors, rather than TCS PIM-1 1; the most potent pyridone inhibitor exhibited an IC50 of 50 nM for Pim-1 kinase inhibition in vitro. Structural-activity relationship (SAR) analysis was conducted to outline the structural requirements for in vitro Pim-1 kinase inhibitory activity of substituted pyridones. X-ray crystallography revealed a hydrogen bond matrix involving the potent pyridone inhibitor, two water molecules, and the catalytic core of Pim-1 kinase, along with a potential weak hydrogen bond between an aromatic hydrogen on the R1 phenyl ring of the inhibitor and a main-chain carbonyl of Pim-1 kinase, which accounted for the high potency of the inhibitor [1] |
| ln Vivo |
Mouse model of IBD was established by the treatment with trinitrobenzene sulphonic acid (TNBS). The results showed that disease activity index score was significantly decreased, colon length was significantly increased while Wallace score and pathological score were significantly decreased after PIM-Inh treatment compared to TNBS model group. In addition, GATA3 and ROR-γt mRNA and protein levels significantly increased but Foxp3 mRNA and protein levels significantly decreased in mice with TNBS treatment compared to mice without TNBS treatment. Administration of PIM-Inh caused significant decreases in GATA3, T-bet and ROR-γt mRNA and protein levels as well as significant increases in FOXP3 mRNA and protein levels.
|
| Animal Protocol |
Mouse model of IBD |
| References | |
| Additional Infomation |
3-Cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone is a pyridone compound with the structure 2-pyridone, substituents at positions 3, 4, and 6, namely cyano, phenyl, and 3-bromo-6-hydroxyphenyl. It is a pyridone, bromophenol, and nitrile.
|
| Molecular Formula |
C18H11BRN2O2
|
|
|---|---|---|
| Molecular Weight |
367.2
|
|
| Exact Mass |
366
|
|
| Elemental Analysis |
C, 58.88; H, 3.02; Br, 21.76; N, 7.63; O, 8.71
|
|
| CAS # |
491871-58-0
|
|
| Related CAS # |
|
|
| PubChem CID |
1235170
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.6±0.1 g/cm3
|
|
| Boiling Point |
592.6±50.0 °C at 760 mmHg
|
|
| Flash Point |
312.2±30.1 °C
|
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
|
| Index of Refraction |
1.728
|
|
| LogP |
4.6
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
23
|
|
| Complexity |
595
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
BrC1C([H])=C([H])C(=C(C=1[H])C1=C([H])C(=C(C#N)C(N1[H])=O)C1C([H])=C([H])C([H])=C([H])C=1[H])O[H]
|
|
| InChi Key |
SVSYJTYGPLVUOZ-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C18H11BrN2O2/c19-12-6-7-17(22)14(8-12)16-9-13(11-4-2-1-3-5-11)15(10-20)18(23)21-16/h1-9,22H,(H,21,23)
|
|
| Chemical Name |
6-(5-bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1H-pyridine-3-carbonitrile
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7233 mL | 13.6166 mL | 27.2331 mL | |
| 5 mM | 0.5447 mL | 2.7233 mL | 5.4466 mL | |
| 10 mM | 0.2723 mL | 1.3617 mL | 2.7233 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA